Atea
atea.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Atea is a Norwegian information technology company with roots going back to 1968 and headquartered in Oslo. It is the largest IT infrastructure supplier in the Nordic and Baltic region. The company is listed on the Oslo Stock Exchange.
News
Atea Pharmaceuticals Eyes 2028 Launch After Strong Phase 3
Detailed price information for Atea Pharmaceuticals Inc (AVIR-Q) from The Globe and Mail including charting and trades.
Read more
Report
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 Trial Outside North America on Track wit
Read more
Report
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a Global Phase 3 Program of Hepatitis C
Read more
Report
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
--Atea Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company developing oral antiviral therapeutics for serious viral diseases, today announced positive topline results from C-BEYOND, its pivotal Phase 3 trial conducted in North America e
Read more
Report
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Detailed price information for Atea Pharmaceuticals Inc (AVIR-Q) from The Globe and Mail including charting and trades.
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.